Bioavailability Study of Clonazepam ODT Under Fasting Conditions

This study has been completed.
Sponsor:
Collaborator:
Gatway Medical Research, Inc
Information provided by:
Par Pharmaceutical, Inc.
ClinicalTrials.gov Identifier:
NCT00652912
First received: April 1, 2008
Last updated: April 3, 2008
Last verified: April 2008

April 1, 2008
April 3, 2008
March 2004
April 2004   (final data collection date for primary outcome measure)
Rate and Extent of Absorption [ Time Frame: 24 Hours ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00652912 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Bioavailability Study of Clonazepam ODT Under Fasting Conditions
Comparative, Randomized, Single-Dose, Bioavailability Study of Kali's Clonazepam ODT 1 mg With That of Klonopin Wafers 1 mg ODT in Healthy Adult Subjects Under Fasting Conditions.

To compare the single-dose bioavailability of Clonazepam ODT 1 mg and Klonopin Wafers 1 mg ODT

To compare the single -dose bioavailability of kali's Clonazepam ODT 1 mg with that of Klonopin Wafers 1 mg ODT by Roche pharmaceuticals following a single oral dose under fasting conditions.

Interventional
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
To Determine Bioequivalence Under Fasting Conditions
  • Drug: Clonazepam
    ODT, 1 mg
    Other Name: Klonopin Wafers
  • Drug: Klonopin Wafers
    ODT, 1 mg
    Other Name: Clonazepam ODT
  • Experimental: A
    Subjects received the Kali formulated products under fasting conditions
    Intervention: Drug: Clonazepam
  • Active Comparator: B
    Subjects received the Roche's product under fasting conditions
    Intervention: Drug: Klonopin Wafers
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
32
May 2004
April 2004   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • All subjects selected for this study will be alt least 18 years of age.Females must be of non- childbearing potential (postmenopausal for alt least 6 months or surgically sterile)
  • Each subject shall be given a general physical examination within 28 days of the study. Such examination includes, but is not limited to, blood pressure, general observations, and history.
  • Each female subject will be given a serum pregnancy test as part of the pre-study process.
  • At the end of the study, the subjects will have an exit evaluation consisting of interim history, global evaluation, and clinical laboratory measurements.
  • Adequate blood and urine samples should be obtained within 28 days before beginning of the first period and at the end of the trail for clinical laboratory.
  • Clinical laboratory measurements will include the following:
  • Hematology: hemoglobin, hematocrit, red blood cell count (with differential)
  • Clinical Chemistry: creatinine, BUN, glucose, SGOT/ AST, SGPT/ALT, bilirubin, and alkaline phosphate.
  • Urine Analysis: pH, specific gravity, protein, glucose, ketones, bilirubin, occult blood and cells.
  • HIV Screen: (Pre-study only)
  • Hepatitis-B, C Screen: (Pre-study only)
  • Drugs of Abuse Screen: (Pre-study at check -in each dosing period)
  • Electrocardiograms of all participating subjects will be recorded before initiation of the study and filed with each subject's case report forms.

Exclusion Criteria:

  • Subjects with a history of chronic alcohol consumption (during past 2 years), drug addiction, or serious gastrointestinal, renal, hepatic or cardiovascular disease, tuberculosis epilepsy, asthma, (during pat 5 years), diabetes, psychosis or glaucoma will not be eligible for this study.
  • Subjects whose clinical laboratory test values are outside the normal range may be retested at the discretion of the clinical investigator. If the clinical values are outside the range on retesting, the subject will not be eligible to participate in the study unless the clinical investigator deems the result to not be significant.
  • Subjects who have a history of allergic response to the class of drug being tested should excluded form the study.
  • All subjects will have urine samples assayed for the presence of drugs of abuse as part of the clinical laboratory screening procedures and check in each dosing period. Subjects found to have urine concentration of any of the tested drugs will not be allowed to participate.
  • Subjects should not have donated blood and/plasma for at least thirty (30) days prior to the first dosing of the study
  • Subjects who have taken any investigational drug within thirty (30) days prior to the first dosing of the study will not be allowed to participate.
  • Female subjects with childbearing potential will not be allowed to participate.
  • All female subjects will be screened for pregnancy at check in each study period.
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00652912
B043204
No
Dr. Alfred Elvin/ Director Biopharmaceutics, Par Pharmaceutical, Inc.
Par Pharmaceutical, Inc.
Gatway Medical Research, Inc
Principal Investigator: Ali Ziaee Cetero Research, San Antonio
Study Director: Gary Shillito Cetero Research, San Antonio
Par Pharmaceutical, Inc.
April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP